What the Market Is Really Implying

The conventional discounted cash flow model starts with a forecast and produces a price target. The reverse DCF starts with today's market price and asks what forecast would justify it. This is not a semantic distinction. It is a different epistemological frame.

A standard DCF requires you to forecast revenue growth, margins, working capital, capex, and WACC for ten years and then compute a terminal value. Any analyst willing to spend enough time on those inputs can produce a model that arrives at almost any price target. The model is as accurate as the assumptions, and the assumptions are the thing in dispute. The reverse DCF sidesteps this by treating the market price as the answer to the DCF and working backwards to the question it is implicitly answering.

The key mechanism is the revenue growth decay model. Rather than projecting a single flat growth rate, the model uses a decay factor d: each year's growth is d times the prior year's. At d = 0.83 — the S&P 500 median — a company entering the forecast period at 20% growth converges to roughly 2% by year ten. At d = 0.92 — high-growth SaaS — it converges to roughly 7%. The solver finds the decay rate that makes today's enterprise value equal the present value of projected free cash flows plus a terminal value. That decay rate is the market's embedded assumption.

The output is not a price target. It is a calibrated question: the market is pricing this company as if it will sustain growth persistence above the S&P 500 top quartile but below best-in-class recurring revenue businesses. Is that plausible? The answer requires industry knowledge, competitive position analysis, and an understanding of the sector's structural tailwinds and headwinds — none of which the model supplies. The model surfaces the assumption; the investor provides the judgment.

The seven quality scores address a narrower question than the price analysis: is the financial history of this business pointing toward soundness or deterioration? Each score tests a different dimension of that question.

The Piotroski F-Score (0-9) aggregates nine financial signals across profitability, leverage, and operating efficiency. A score of 8 or 9 means recent financial history is improving on almost every dimension that historically separates winners from losers in value screens. A score of 3 or below means the opposite. The F-Score does not assess whether the valuation is reasonable; it assesses whether the financial momentum is positive.

The Altman Z-Score tests for the pattern of financial deterioration that preceded historical bankruptcies. A score above 2.99 on the manufacturing model (above 2.60 on the non-manufacturing model) is in the safe zone — not a prediction of long-term success, but the absence of the specific warning pattern that characterized distressed companies before they failed. Grey zone scores deserve attention; distress zone scores require an explanation.

The Greenwald EPV per share is the equity value of the current business sustained at normalized profitability with no growth embedded. It is a conservative floor, not a price target. A stock trading below its EPV per share is being priced as if the business will contract — a specific claim that should be either confirmed by the analysis or rejected as mispricing.

The Beneish M-Score applies an eight-variable model to detect whether the financial ratios resemble patterns observed in historical earnings manipulation cases. The most sensitive variable is total accruals to total assets, which is the dominant channel through which aggressive accounting tends to inflate reported earnings. A score above −1.78 is a flag, not a conviction: it means the pattern warrants examination of the receivables policy, deferred revenue, and non-recurring items in the 10-K narrative.

Molina Healthcare provides a concrete illustration of how the two tools interact. The following numbers are drawn from the live scorecard at /api/valuation/MOH as of April 2026. They are illustrative of the reading, not canonical — the underlying scores re-derive on each filing cycle and DB refresh, so readers checking the live endpoint may see updated values.

On the quality side, the scorecard returns a Piotroski F-Score of 4/9 — neutral territory. Four of the nine financial signals are positive; five are not. The Altman Z-Score is 3.6, which places Molina in the safe zone using the non-manufacturing model. Total Shareholder Yield is 13.2%, reflecting meaningful capital return through buybacks. EPV per share is $225.94, computed from normalized EBIT at a conservative WACC using Greenwald's framework.

The F-Score of 4 is worth examining specifically. Managed care is a capital-light, high-revenue business with thin margins and high asset turnover. Several Piotroski signals — gross margin trend, asset turnover improvement — are sensitive to single-year enrollment and reimbursement rate fluctuations. A 4 in this sector context is not the same early warning signal it would be for a deteriorating industrial manufacturer. The score is a starting point for the question, not the answer to it.

The Z-Score of 3.6 in the safe zone is consistent with what a financially stable managed-care company should produce: positive retained earnings, positive working capital, reasonable EBIT relative to total assets, and a market capitalization that covers total liabilities. None of these figures show the pattern that precedes bankruptcy.

The TSY of 13.2% is the most meaningful single number in the quality battery for a company with MOH's capital structure. Managed care generates high revenue per dollar of assets but earns narrow margins; the capital return is the mechanism through which value accrues to shareholders. A 13.2% TSY on a stable business is substantial. It suggests management is returning capital at a rate that compensates for the low-margin structure.

EPV per share of $225.94 is the current-operations floor. At a market price well above $225.94, the stock is being priced for some combination of growth and continued capital return beyond what the current earnings power sustains at flat margins. The reverse DCF is the tool that characterizes what specifically the market is expecting on the growth side.

The phrase “this stock is cheap” is incomplete without specifying cheap relative to what. Cheap relative to its implied growth assumptions is a meaningful observation only if the business is capable of executing on some growth story at all. Cheap relative to earnings power is a meaningful observation only if the earnings power is real and not manufactured through aggressive accruals.

The reverse DCF addresses the price anchor: given today's market price, what is the market implying? The value scores address the quality anchor: is the business behind that price financially sound, improving, and honest in its reporting? The combination is not additive — it is sequenced. A stock that fails the quality filters at a level that cannot be explained by industry-specific accounting conventions is not a candidate for detailed reverse DCF work, regardless of what implied growth rate the solver returns. A stock that passes the quality filters but is priced for growth persistence in the Cisco-2000 cohort is a candidate for detailed scrutiny of whether that persistence is achievable, regardless of how strong the financial history looks.

The relationship between the two tools runs in both directions. A Greenwald EPV per share of $225.94 against a market price well above that level defines a specific growth premium the market is assigning. The reverse DCF decomposes that premium into an implied decay rate. The decay rate is then compared against the base-rate cohorts to answer: is the market asking for something that companies in comparable situations have historically delivered? That is a tractable question. It is not a forecast, but it is a bounded, well-specified disagreement.

The valuation module occupies the intrinsic-value anchoring layer of the research stack. It is the third of four tools, each of which addresses a different time horizon and type of evidence.

Language Analysis (the first tool) scans SEC filing text for changes in sentiment, emphasis, and lexical pattern across quarters. It is an early-warning system: management tone shifts and risk factor expansions tend to precede financial deterioration by one to three reporting periods. It answers the question of whether the narrative is changing before the numbers change.

Signal Sweep (the second tool) runs sixty-two technical indicators across a peer group to identify which signals — at which horizons — have produced positive expected value historically. It operates on price history and addresses the timing question: given a thesis that holds at the fundamental level, when have historical signal patterns been associated with positive forward returns in peer companies?

Valuation (this tool) anchors the analysis to intrinsic value. It makes explicit what growth assumption the current price implies and whether the business behind that price is financially sound. The output is not a timing signal but a calibration: the price is rational if and only if the embedded growth assumption is believable, and the business is capable of executing on it only if the quality battery indicates financial soundness.

The RE vs Index paper sits outside this stack — it addresses asset-class conviction rather than individual security selection. Its question is whether the equity asset class deserves a position in a retirement portfolio relative to residential real estate, after properly pricing the landlord's labor. The valuation module operates within equities on the assumption that the asset-class case has already been made.

The practical workflow is sequential. Language Analysis flags a potential shift in a company's narrative. Signal Sweep identifies whether the sector is showing historically reliable timing signals. Valuation anchors the price analysis and quality check. Position cards capture the thesis, the entry rules, and the conditions under which the thesis breaks. No position is taken without passing through all layers.